EKOS™ Control Unit 4.0 Simplifies Treatment of Blood Clots
BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS™ CU 4.0 units have been shipped from BTG’s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS™ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS™ devices simultaneously.
These improvements simplify bilateral treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT). Using CU 4.0, physicians can treat both pulmonary arteries and can easily monitor and manage two EKOS™ devices at the same time.
European patients with PEs and DVTs have already successfully been treated with EKOS™ CU 4.0 during a limited release of the product.
Professor Nils Kucher, Director of Clinic of Angiology at University Hospital in Zurich, Switzerland said: “I’ve used EKOS™ therapy for over 10 years. This latest innovation of the technology is a big step for simplifying thrombosis treatment.”
EKOS™ is the only device to have both FDA Clearance and a CE Mark  for the treatment of PE. The system includes an ultrasonic device that uses acoustic pulses, which enable quick and safe dissolution of blood clots and restore blood flow in patients with PE, DVT and peripheral arterial occlusions.
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer and vascular conditions. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.
EKOS is a registered trademark of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International LTD.
Product availability varies by country. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Prior to use, please refer to the applicable Instructions for Use (IFU) for complete product indications, contraindications, warnings, and precautions.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-MSCI16.7.2019 16:51:06 CEST | Press release
MSCI Schedules Investor Conference Call to Review Second Quarter 2019 Results
KEIO-PLAZA-HOTEL-TOKYO16.7.2019 16:07:03 CEST | Press release
Keio Plaza Hotel Tokyo Offers “Tea Ceremony Experience and Luxurious Accommodations for Families” Package
LIVANOVA-PLC16.7.2019 15:02:10 CEST | Press release
LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula
CA-MERCATUS16.7.2019 15:02:09 CEST | Press release
Mercatus Opens UK Office; Hires Chris Webb to Lead European Operations
NY-MOODY’S/EQUISTONE16.7.2019 14:33:28 CEST | Press release
Moody’s to Sell Moody’s Analytics Knowledge Services Business
CA-KITE16.7.2019 14:32:07 CEST | Press release
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom